New Delhi ramped up scrutiny of Chinese businesses after a 2020 border clash between the two countries, banning more than 300 Chinese apps, including TikTok. India has also intensified scrutiny of investments by Chinese firms.

Read More

​ New Delhi ramped up scrutiny of Chinese businesses after a 2020 border clash between the two countries, banning more than 300 Chinese apps, including TikTok. India has also intensified scrutiny of investments by Chinese firms. New Delhi ramped up scrutiny of Chinese businesses after a 2020 border clash between the two countries, banning more than 300 Chinese apps, including TikTok. India has also intensified scrutiny of investments by Chinese firms.  Moneycontrol Latest News Read More  

New Delhi ramped up scrutiny of Chinese businesses after a 2020 border clash between the two countries, banning more than 300 Chinese apps, including TikTok. India has also intensified scrutiny of investments by Chinese firms.

The National Coal Index (NCI) is a price index that combines coal prices from all sales channels, including notified prices, auction prices and import prices.

Read More

​ The National Coal Index (NCI) is a price index that combines coal prices from all sales channels, including notified prices, auction prices and import prices. The National Coal Index (NCI) is a price index that combines coal prices from all sales channels, including notified prices, auction prices and import prices.  Moneycontrol Latest News Read More  

The National Coal Index (NCI) is a price index that combines coal prices from all sales channels, including notified prices, auction prices and import prices.

The United States Food and Drug Administration (USFDA) inspected the Unit I, a Formulation manufacturing facility, of Eugia Pharma Specialities

Read More

​ The United States Food and Drug Administration (USFDA) inspected the Unit I, a Formulation manufacturing facility, of Eugia Pharma Specialities The United States Food and Drug Administration (USFDA) inspected the Unit I, a Formulation manufacturing facility, of Eugia Pharma Specialities  Moneycontrol Latest News Read More  

The United States Food and Drug Administration (USFDA) inspected the Unit I, a Formulation manufacturing facility, of Eugia Pharma Specialities

Revenue is likely to come in at Rs 4,729.7 crore for the quarter under review, implying a 6 percent YoY growth and a 1 percent drop sequentially. The slight increase in revenue is most likely due to higher volumes, analysts believe

Read More

​ Revenue is likely to come in at Rs 4,729.7 crore for the quarter under review, implying a 6 percent YoY growth and a 1 percent drop sequentially. The slight increase in revenue is most likely due to higher volumes, analysts believe Revenue is likely to come in at Rs 4,729.7 crore for the quarter under review, implying a 6 percent YoY growth and a 1 percent drop sequentially. The slight increase in revenue is most likely due to higher volumes, analysts believe  Moneycontrol Latest News Read More  

Revenue is likely to come in at Rs 4,729.7 crore for the quarter under review, implying a 6 percent YoY growth and a 1 percent drop sequentially. The slight increase in revenue is most likely due to higher volumes, analysts believe

Although the decision to move the no-confidence motion is that of the united opposition, Gogoi, who is an MP from Assam, will move the motion, he said.

Read More

​ Although the decision to move the no-confidence motion is that of the united opposition, Gogoi, who is an MP from Assam, will move the motion, he said. Although the decision to move the no-confidence motion is that of the united opposition, Gogoi, who is an MP from Assam, will move the motion, he said.  Moneycontrol Latest News Read More  

Although the decision to move the no-confidence motion is that of the united opposition, Gogoi, who is an MP from Assam, will move the motion, he said.

Dixon Technologies has posted a return of 52.11 percent over the last six months, outperforming the Nifty Midcap 100 index which has given a return of 20.18 percent over the same duration

Read More

​ Dixon Technologies has posted a return of 52.11 percent over the last six months, outperforming the Nifty Midcap 100 index which has given a return of 20.18 percent over the same duration Dixon Technologies has posted a return of 52.11 percent over the last six months, outperforming the Nifty Midcap 100 index which has given a return of 20.18 percent over the same duration  Moneycontrol Latest News Read More  

Dixon Technologies has posted a return of 52.11 percent over the last six months, outperforming the Nifty Midcap 100 index which has given a return of 20.18 percent over the same duration

Shree Cement’s board also approved investment worth Rs 7,000 crore for increasing capacity by way of internal accruals and debt.

Read More

​ Shree Cement’s board also approved investment worth Rs 7,000 crore for increasing capacity by way of internal accruals and debt. Shree Cement’s board also approved investment worth Rs 7,000 crore for increasing capacity by way of internal accruals and debt.  Moneycontrol Latest News Read More  

Shree Cement’s board also approved investment worth Rs 7,000 crore for increasing capacity by way of internal accruals and debt.

Inoperative PANs have been giving a headache to non-resident Indians. Unresponsive jurisdictional assessment officers, lack of online facility to contact them to update residential status and non-receipt of e-verification codes continue to impede smooth filing of NRI tax returns.

Read More

​ Inoperative PANs have been giving a headache to non-resident Indians. Unresponsive jurisdictional assessment officers, lack of online facility to contact them to update residential status and non-receipt of e-verification codes continue to impede smooth filing of NRI tax returns. Inoperative PANs have been giving a headache to non-resident Indians. Unresponsive jurisdictional assessment officers, lack of online facility to contact them to update residential status and non-receipt of e-verification codes continue to impede smooth filing of NRI tax returns.  Moneycontrol Latest News Read More  

Inoperative PANs have been giving a headache to non-resident Indians. Unresponsive jurisdictional assessment officers, lack of online facility to contact them to update residential status and non-receipt of e-verification codes continue to impede smooth filing of NRI tax returns.

ICICI Securities recommended hold rating on Ashok Leyland with a target price of Rs 185 in its research report dated July 25, 2023.

Read More

​ ICICI Securities recommended hold rating on Ashok Leyland with a target price of Rs 185 in its research report dated July 25, 2023. ICICI Securities recommended hold rating on Ashok Leyland with a target price of Rs 185 in its research report dated July 25, 2023.  Moneycontrol Latest News Read More  

ICICI Securities recommended hold rating on Ashok Leyland with a target price of Rs 185 in its research report dated July 25, 2023.

Yatharth Hospital IPO | The offer comprises a fresh issue of Rs 490 crore by the company and an offer for sale of 65.51 lakh equity shares by promoters Vimla Tyagi, Prem Narayan Tyagi and Neena Tyagi.

Read More

​ Yatharth Hospital IPO | The offer comprises a fresh issue of Rs 490 crore by the company and an offer for sale of 65.51 lakh equity shares by promoters Vimla Tyagi, Prem Narayan Tyagi and Neena Tyagi. Yatharth Hospital IPO | The offer comprises a fresh issue of Rs 490 crore by the company and an offer for sale of 65.51 lakh equity shares by promoters Vimla Tyagi, Prem Narayan Tyagi and Neena Tyagi.  Moneycontrol Latest News Read More  

Yatharth Hospital IPO | The offer comprises a fresh issue of Rs 490 crore by the company and an offer for sale of 65.51 lakh equity shares by promoters Vimla Tyagi, Prem Narayan Tyagi and Neena Tyagi.